Ben H Chew1,2, Andre A Matteliano3, Thomas de Los Reyes1, Michael E Lipkin2,4, Ryan F Paterson1, Dirk Lange1,2. 1. 1 Department of Urologic Sciences, University of British Columbia , Vancouver, Canada . 2. 2 Endourology Disease Group for Excellence (EDGE) Research Consortium Member. 3. 3 Section of Urology, Department of Surgery, University of Manitoba , Winnipeg, Canada . 4. 4 Division of Urology, Department of Surgery, Duke University Medical Center , Durham, North Carolina.
Abstract
PURPOSE: Standardized bench testing of the new ShockPulse™ intracorporeal lithotripter was performed against three commercially available lithotripsy systems to determine differences and nuances in performance. MATERIALS AND METHODS: The ShockPulse intracorporeal lithotripter was tested against the LUS-2™, CyberWand,™ and EMS LithoClast™ in a standardized bench setting using hard (Ultracal-30) and soft (plaster of Paris) stone phantoms. An in vitro kidney model was used to record the time needed to fragment stone samples into retrievable-sized pieces. The time needed to fully comminute and evacuate stone samples was also recorded. The efficacy of each device at various applied pressures was determined using a hands-free apparatus, which was used to apply 1.0, 1.5, and 2.0 pounds of fixed force. RESULTS: For hard and soft stones, the time needed to create retrievable fragments was similar among all systems (p = 0.585). The ShockPulse was significantly faster than the LUS-2 and LithoClast at fully fragmenting and evacuating stone samples (p = 0.046), while the CyberWand was significantly slower than all three systems at this task (p = 0.001). When fixed forces were applied to a large stone phantom, the ShockPulse and CyberWand were significantly faster than the LUS-2 and LithoClast (p < 0.0001). When groups of smaller stones were tested, the ShockPulse was significantly faster at 1.0 pound (p < 0.001) and 1.5 pounds (p < 0.002) of force. At 2.0 pounds, no differences were observed (p = 0.09). CONCLUSIONS: The ShockPulse is equally as effective and, in some circumstances, more effective than the three commercially available devices against which it was tested in an in vitro setting.
PURPOSE: Standardized bench testing of the new ShockPulse™ intracorporeal lithotripter was performed against three commercially available lithotripsy systems to determine differences and nuances in performance. MATERIALS AND METHODS: The ShockPulse intracorporeal lithotripter was tested against the LUS-2™, CyberWand,™ and EMS LithoClast™ in a standardized bench setting using hard (Ultracal-30) and soft (plaster of Paris) stone phantoms. An in vitro kidney model was used to record the time needed to fragment stone samples into retrievable-sized pieces. The time needed to fully comminute and evacuate stone samples was also recorded. The efficacy of each device at various applied pressures was determined using a hands-free apparatus, which was used to apply 1.0, 1.5, and 2.0 pounds of fixed force. RESULTS: For hard and soft stones, the time needed to create retrievable fragments was similar among all systems (p = 0.585). The ShockPulse was significantly faster than the LUS-2 and LithoClast at fully fragmenting and evacuating stone samples (p = 0.046), while the CyberWand was significantly slower than all three systems at this task (p = 0.001). When fixed forces were applied to a large stone phantom, the ShockPulse and CyberWand were significantly faster than the LUS-2 and LithoClast (p < 0.0001). When groups of smaller stones were tested, the ShockPulse was significantly faster at 1.0 pound (p < 0.001) and 1.5 pounds (p < 0.002) of force. At 2.0 pounds, no differences were observed (p = 0.09). CONCLUSIONS: The ShockPulse is equally as effective and, in some circumstances, more effective than the three commercially available devices against which it was tested in an in vitro setting.
Authors: Maximilian Eisel; Markus J Bader; Frank Strittmatter; Udo Nagele; Christian G Stief; Thomas Pongratz; Ronald Sroka Journal: World J Urol Date: 2020-04-10 Impact factor: 4.226
Authors: Tomas Andri Axelsson; Cecilia Cracco; Mahesh Desai; Mudhar Nazar Hasan; Thomas Knoll; Emanuele Montanari; Daniel Pérez-Fentes; Michael Straub; Kay Thomas; James C Williams; Marianne Brehmer; Palle J S Osther Journal: World J Urol Date: 2020-07-29 Impact factor: 4.226